Edition:
United States

Quidel Corp (QDEL.OQ)

QDEL.OQ on NASDAQ Stock Exchange Global Select Market

40.34USD
3:59pm EST
Change (% chg)

$-0.06 (-0.15%)
Prev Close
$40.40
Open
$40.26
Day's High
$40.62
Day's Low
$40.00
Volume
72,004
Avg. Vol
130,990
52-wk High
$45.49
52-wk Low
$18.25

Chart for

About

Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. These diagnostic testing solutions are separated into four product categories: immunoassays, molecular assays, virology and specialty products. The Company sells its products directly to end users and distributors, in... (more)

Overall

Beta: 1.14
Market Cap(Mil.): $1,373.47
Shares Outstanding(Mil.): 34.00
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 28.09 15.67
EPS (TTM): -- -- --
ROI: -- 9.98 34.62
ROE: -- 15.22 16.00

BRIEF-Quidel Says Confident In Validity Of Supply Agreement With Beckman Coulter To Sell BNP Assay Assets

* QUIDEL CONFIDENT IN LEGAL STRENGTH AND VALIDITY OF SUPPLY AGREEMENT WITH BECKMAN COULTER TO SELL BNP ASSAY ASSETS

Nov 27 2017

BRIEF-Quidel Corp reports Q3 GAAP loss per share $0.16

* Q3 earnings per share view $-0.04 -- Thomson Reuters I/B/E/S

Nov 01 2017

BRIEF-Quidel receives FDA clearance for its point-of-care Sofia® Lyme FIA

* Quidel receives FDA clearance for its point-of-care Sofia® Lyme FIA

Oct 23 2017

BRIEF-Quidel gets FDA nod for Solana Assay molecular diagnostic test

* Quidel receives FDA clearance for its Solana RSV + hMPV Assay

Oct 17 2017

BRIEF-Quidel Corp says ‍on Oct 6, co entered into credit agreement​

* Quidel corp says ‍on Oct 6, co entered into credit agreement​ - sec filing

Oct 06 2017

BRIEF-QUIDEL ANNOUNCES EARLY TERMINATION OF HART-SCOTT-RODINO WAITING PERIOD ON DEAL FOR ALERE'S ASSAY BUSINESS

* QUIDEL ANNOUNCES EARLY TERMINATION OF THE HART-SCOTT-RODINO WAITING PERIOD FOR ITS PENDING ACQUISITION OF ALERE’S TRIAGE® B-TYPE NATURIETIC PEPTIDE (BNP) ASSAY BUSINESS RUN ON BECKMAN COULTER ANALYZERS

Sep 28 2017

BRIEF-Quidel announces revised agreement for pending acquisition of Alere’s business

* Quidel announces revised agreement for its pending acquisition of Alere’s B-type Naturietic Peptide (BNP) assay business run on Beckman Coulter Analyzers

Sep 18 2017

BRIEF-Quidel Q2 GAAP loss per share $0.35

* Q2 earnings per share view $-0.18 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

Jul 26 2017

BRIEF-Quidel announces definitive agreement to acquire Alere Triage assets

* Quidel Corp - ‍accretive transactions extend Quidel's market leadership and position it for future growth​

Jul 17 2017

BRIEF-Quidel receives FDA clearance and CLIA waiver

* Quidel receives FDA clearance and CLIA waiver for its point-of-care sofia 2 instrument for use with sofia respiratory syncytial virus (RSV) assay Source text for Eikon: Further company coverage:

Jun 28 2017

Earnings vs. Estimates